PressNovember 13, 2025 MindBio's Phase 2b take-home LSD microdosing trial underperforms placebo in major depression
PressNovember 13, 2025 Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs
PressNovember 10, 2025 AtaiBeckley posts positive Phase 2b open-label extension data for BPL-003 in treatment-resistant depression
PressNovember 6, 2025 GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data
PressOctober 28, 2025 Delix reports positive Phase 1b data for non-hallucinogenic DLX-001 and FDA clearance of at-home Phase 2
PressOctober 23, 2025 Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy
PressOctober 16, 2025 FDA grants Breakthrough Therapy designation to BPL-003 for treatment-resistant depression
